2BB score and signals
Aldeyra Therapeutics, Inc.’s current 2BB score is 13 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 0 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 17 | Very Weak |
| Quality | 20 | Weak |
| Risk | 45 | Moderate |
Company facts
| CEO | Todd C. Brady M.D., Ph.D. |
| Headquarters | Lexington, Massachusetts, United States |
| Founded | 2004 |
| Employees | 6 |
| 52-week range | $0.79 – $5.93 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-25 | — | -0.1 | — | $0.00 |
| 2026-11-02 | — | -0.0959 | — | $0.00 |
| 2026-08-05 | — | -0.0959 | — | $0.00 |
| 2026-05-07 | -0.06 | -0.0995 | $0.00 | $0.00 |
Related companies
2BBBullish & Bearish